Department of Orthopaedic Surgery, Division of Sports Medicine, NYU Langone Health, New York, NY, USA.
Phys Sportsmed. 2023 Jun;51(3):223-227. doi: 10.1080/00913847.2021.2025163. Epub 2022 Jan 24.
As platelet-rich plasma injection for knee osteoarthritis (OA) has increased in popularity, it has become more important to assess its effectiveness and satisfaction with its use in the context of its high cost. The purpose of this study was to determine satisfaction, commercial appeal, and effectiveness of platelet-rich plasma (PRP) for the treatment of knee OA.
A retrospective review of patients who underwent PRP injection in the knee from 2016 to 2019 was performed. Various patient-reported outcomes were collected, including: satisfaction with the PRP injection (out of 100), whether the patient would want to undergo PRP injection again, whether they would recommend the injection and whether they felt that the injection was worth the cost was collected. VAS pain scores were collected and measured out of 100. Demographics and radiographical information were obtained via chart review. Statistical analyses were conducted including descriptive statistics and binary logistic and linear regressions.
Overall, 114 patients were included. The mean pre-injectionpain score was 70.4, and the mean pain level decreased after injection to 36.8. Patients rated their satisfaction on average as neutral along the aforementioned continuous scale (49.2), , 50.9% stated that they would get the PRP injection again, 60.5% would recommend to a friend, and 50.9% felt the injection was worth the cost. Younger age and improved post-injection pain correlated with increasing likelihood of desiring further PRP injection.
Patients on average rated satisfaction slightly below average, indicating net neutrality in terms of satisfaction with their injection. Furthermore, only half of the patients indicated that it was worth the cost and that they would receive it again. Younger age and post-injection pain relief increased desire for further injection, but pain-relief did not correlate with patients saying that the injection was worth the cost.
随着富血小板血浆（PRP）注射治疗膝骨关节炎（OA）的普及，评估其在高成本背景下的有效性和满意度变得越来越重要。本研究旨在确定 PRP 治疗膝骨关节炎的满意度、商业吸引力和有效性。
对 2016 年至 2019 年期间接受膝关节 PRP 注射治疗的患者进行回顾性研究。收集了各种患者报告的结果，包括：对 PRP 注射的满意度（满分 100 分）、患者是否希望再次接受 PRP 注射、是否会推荐该注射以及是否认为该注射物物有所值。还收集了 VAS 疼痛评分，满分为 100 分。通过图表审查获取人口统计学和影像学信息。进行了描述性统计分析以及二元逻辑回归和线性回归分析。
共有 114 名患者入组。注射前平均疼痛评分为 70.4，注射后平均疼痛水平降低至 36.8。患者在上述连续量表上的平均满意度评分为中性（49.2），50.9%的患者表示会再次接受 PRP 注射，60.5%的患者会推荐给朋友，50.9%的患者认为该注射物物有所值。年轻的年龄和注射后疼痛的改善与进一步接受 PRP 注射的可能性增加相关。
患者平均满意度评分略低于平均水平，表明患者对注射的满意度为中性。此外，只有一半的患者表示物有所值且会再次接受该治疗。年轻的年龄和注射后疼痛缓解增加了进一步注射的欲望，但疼痛缓解与患者认为该注射物物有所值之间没有相关性。
